Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of huCART19-IL18 in CD19+ Cancers
NCT04684563Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- May 2021
- Primary completion
- May 2036
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of huCART19-IL18 in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) (4 cohorts), sponsored by University of Pennsylvania. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 15 years, Occurrence of dose-limiting toxicities at 28 days and 3 more. Started May 2021; status: active, not recruiting.
02
Drugs
huCART19-IL18
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04684563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684563.